• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    1/3/23 12:30:47 PM ET
    $AMAM
    $ATNF
    $CANO
    $DRMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMAM alert in real time by email

    Gainers

    • Jasper Therapeutics (NASDAQ:JSPR) shares moved upwards by 576.1% to $3.27 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 39.7 million shares, making up 55465.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $121.0 million.
    • Lucira Health (NASDAQ:LHDX) stock increased by 512.33% to $0.68. Trading volume for Lucira Health's stock is 119.7 million as of 12:30 EST. This is 35583.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $27.6 million.
    • Reshape Lifesciences (NASDAQ:RSLS) shares moved upwards by 96.73% to $13.26. The current volume of 8.8 million shares is 28689.1% of Reshape Lifesciences's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $6.4 million.
    • Scilex Holding (NASDAQ:SCLX) shares rose 41.6% to $5.65. Scilex Holding's stock is trading at a volume of 291.0K shares as of 12:30 EST. This is 459.4% of its average full-day volume over the last 100 days. The company's market cap stands at $798.6 million.
    • 180 Life Sciences (NASDAQ:ATNF) stock rose 37.75% to $4.67. 180 Life Sciences's stock is trading at a volume of 23.6 million shares as of 12:30 EST. This is 1125.5% of its average full-day volume over the last 100 days. The company's market cap stands at $17.4 million.
    • Idera Pharmaceuticals (NASDAQ:IDRA) stock moved upwards by 34.28% to $0.47. As of 12:30 EST, Idera Pharmaceuticals's stock is trading at a volume of 653.2K, which is 584.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.3 million.

    Losers

    • Palisade Bio (NASDAQ:PALI) shares declined by 25.4% to $3.88 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 4.1 million shares, making up 139.7% of its average full-day volume over the last 100 days. The company's market cap stands at $5.5 million.
    • Dermata Therapeutics (NASDAQ:DRMA) stock decreased by 24.72% to $0.31. As of 12:30 EST, Dermata Therapeutics's stock is trading at a volume of 2.9 million, which is 189.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.7 million.
    • Scopus BioPharma (NASDAQ:SCPS) stock decreased by 20.76% to $0.1. The market value of their outstanding shares is at $2.2 million.
    • Cano Health (NYSE:CANO) stock declined by 16.43% to $1.15. Cano Health's stock is trading at a volume of 6.1 million shares as of 12:30 EST. This is 49.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $280.0 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares declined by 16.13% to $32.0. The current volume of 4.4 million shares is 249.6% of Kala Pharmaceuticals's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $51.0 million.
    • Ambrx Biopharma (NYSE:AMAM) shares decreased by 16.08% to $1.91. The current volume of 477.5K shares is 14.1% of Ambrx Biopharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $73.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMAM
    $ATNF
    $CANO
    $DRMA

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Jasper Therapeutics Inc.
    $JSPR
    1/13/2026$17.00Buy
    Rodman & Renshaw
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    H.C. Wainwright
    KALA BIO Inc.
    $KALA
    9/29/2025Buy → Neutral
    Ladenburg Thalmann
    KALA BIO Inc.
    $KALA
    9/8/2025$30.00Outperform
    Mizuho
    More analyst ratings

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

    AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industry TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE:TRIP) (FSE: 4YX) (OTCQB:TRUFF) ("Red Light" or the "Company") and Kala Bio, Inc. (NASDAQ:KALA) ("Kala Bio") today announced that Red Light has engaged Kala Bio's with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. ("Fil

    3/18/26 9:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AI Platforms, Data Infrastructure, and Healthcare Innovation Shape the Market Narrative

    DENVER, March 11, 2026 (GLOBE NEWSWIRE) -- A fresh wave of developments across artificial intelligence, healthcare technology, and digital infrastructure is reinforcing a central theme dominating markets: the rapid convergence of AI with data-heavy industries. From biotech platforms deploying autonomous agents to data-center integrators scaling AI infrastructure, companies are positioning themselves to capture value from the next phase of the technology cycle. Leading the narrative is KALA BIO (NASDAQ:KALA), which announced it expects to deploy its first commercial AI agent within approximately two weeks as part of the rebranded Researgency.ai platform. The company is attempting to reposi

    3/11/26 10:00:26 AM ET
    $CYN
    $DOMO
    $KALA
    EDP Services
    Technology
    Computer Software: Prepackaged Software
    Biotechnology: Pharmaceutical Preparations

    Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

    ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company from a clinical-stage biotech into a dual-engine growth story powered by both a proprietary drug pipeline and a scalable AI platform targeting the $180+ billion AI-in-healthcare market. Kala is building the Palantir for biotech, just as Palantir built a $250+ billion company by helping governments and enterprises make sense of massive data, Kala is doing the same for the biotech and pharmaceutical industry through its Researgency.ai platform, deploying purpose-built AI agents that handle the r

    3/11/26 6:30:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    SEC Filings

    View All

    SEC Form D filed by KALA BIO Inc.

    D - KALA BIO, Inc. (0001479419) (Filer)

    3/17/26 4:59:15 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/17/26 4:21:36 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by KALA BIO Inc.

    144 - KALA BIO, Inc. (0001479419) (Subject)

    3/12/26 5:40:34 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, CFO Finley John David converted options into 13,333 shares and sold $6,818 worth of shares (3,896 units at $1.75), increasing direct ownership by 53% to 27,353 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:07:40 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Jasper Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $17.00

    1/13/26 10:20:49 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Regulatory Affairs Bedoya-Toro Munera Maria E bought $1,270 worth of shares (1,000 units at $1.27), increasing direct ownership by 8,333% to 1,012 units (SEC Form 4)

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    3/17/26 5:44:21 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

    Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease Carlsbad, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases, today announced the appointment of James Izanec, MD, AGAF as Vice President, Clinical Development. Dr. Izanec is a physician–scientist with over two decades of clinical and drug development leadership spanning immunology, neuroscience, and gastr

    12/2/25 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Financials

    Live finance-specific insights

    View All

    Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

    67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open label extension study achieved a complete response or well controlled disease at 12 weeks With a median duration of follow up of more than 200 days on 63 participants in the open label extension study, KIT related AEs were low in frequency and predominantly low-grade events that resolved while on study BEACON and open label extension data sets are now sufficient to select doses for the Phase 2b study of briquilimab in CSU planned to commence in the second half of 2026 Company to host conference

    1/8/26 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

    Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briquilimab in asthma Jasper also announces completion of internal BEACON study investigation noting no deviations or issues with drug product utilized Jasper to host conference call and webinar today at 8:00 a.m. ET REDWOOD CITY, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117)

    12/2/25 7:00:00 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

    11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell drive

    6/14/25 10:00:23 AM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMAM
    $ATNF
    $CANO
    $DRMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Jasper Therapeutics Inc.

    SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)

    11/14/24 6:01:49 PM ET
    $JSPR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by KALA BIO Inc.

    SC 13G - KALA BIO, Inc. (0001479419) (Subject)

    11/14/24 4:49:42 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care